JAR细胞

JAR/JAR细胞系/JAR细胞株/JAR胎盘绒毛癌细胞

Cell line name JAR

Synonyms Jar; JAr; JaR

Accession CVCL_0360

Resource Identification Initiative To cite this cell line use: JAR (RRID:CVCL_0360)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Doubling time: ~20-30 hours (DSMZ=ACC-462).

Karyotypic information: Near triploid karyotype (PubMed=33096371).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Caution: Established from the trophoblastic tumor of the placenta of a 24 year old woman, but the cell line is from the male fetus.

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 30.11

Native American 0.66

East Asian, North 2.4

East Asian, South 0

South Asian 1.4

European, North 42.28

European, South 23.14

Disease Gestational choriocarcinoma (NCIt: C4646)

Gestational choriocarcinoma (ORDO: Orphanet_99926)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_XY25 (JAR-G1) CVCL_XY26 (JAR-G1s) CVCL_C8NY (Jar-GnT4a)

CVCL_B7MU (JAR-Smad3/c)

Sex of cell Male

Age at sampling Fetus

Category Cancer cell line

STR profile Source(s): ATCC=HTB-144; CLS=300221; Cosmic-CLP=907175; DSMZ=ACC-462; KCLB=30144

 

Markers:

Amelogenin X,Y

CSF1PO 7,10

D2S1338 20,21

D3S1358 14 (CLS=300221)

14,16,17 (DSMZ=ACC-462)

16,17 (ATCC=HTB-144; KCLB=30144)

D5S818 10,11

D7S820 10,11

D8S1179 14,16

D13S317 11

D16S539 9,10

D18S51 13,17 (CLS=300221)

14,15 (ATCC=HTB-144; DSMZ=ACC-462)

D19S433 12,13

D21S11 28,29 (ATCC=HTB-144; DSMZ=ACC-462)

30 (CLS=300221)

FGA 22

Penta D 9,11 (CLS=300221)

9,14 (ATCC=HTB-144; DSMZ=ACC-462)

Penta E 10,12 (CLS=300221)

8,12 (ATCC=HTB-144; DSMZ=ACC-462)

TH01 6,7

TPOX 8,11

vWA 16,18

 

Run an STR similarity search on this cell line

Publications

DOI=10.1007/BF02619074

Pattillo R.A., Ruckert A.C.F., Hussa R.O., Bernstein R., Delfs E.M.

The JAr cell line -- continuous human multihormone production and controls.

In Vitro 6:398-399(1971)

 

PubMed=7153601

Sasaki S., Katayama P.K., Roesler M., Pattillo R.A., Mattingly R.F., Ohkawa K.

Cytogenetic analysis of choriocarcinoma cell lines.

Nihon Sanka Fujinka Gakkai Zasshi 34:2253-2256(1982)

 

PubMed=4038916; DOI=10.1016/0165-4608(85)90052-4

Sheppard D.M., Fisher R.A., Lawler S.D.

Karyotypic analysis and chromosome polymorphisms in four choriocarcinoma cell lines.

Cancer Genet. Cytogenet. 16:251-258(1985)

 

PubMed=2878840; DOI=10.1016/0020-7292(86)90088-3

Yamashita K., Nakamura T., Shimizu T., Katagiri M., Ikeda H.

Expression of HLA class I and class II antigens in human choriocarcinoma cell lines.

Int. J. Gynaecol. Obstet. 24:301-307(1986)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=2720636; DOI=10.1016/0165-4608(89)90664-X

Surti U., Habibian R.

Chromosomal rearrangement in choriocarcinoma cell lines.

Cancer Genet. Cytogenet. 38:229-240(1989)

 

PubMed=7937597; DOI=10.1016/0143-4004(94)90008-6

Grummer R., Hohn H.-P., Mareel M.M., Denker H.-W.

Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three-dimensional organ culture system.

Placenta 15:411-429(1994)

 

PubMed=7716126; DOI=10.1016/0143-4004(95)90079-9

Mitchell A.M., Yap A.S., Payne E.J., Manley S.W., Mortimer R.H.

Characterization of cell polarity and epithelial junctions in the choriocarcinoma cell line, JAR.

Placenta 16:31-39(1995)

 

PubMed=7819056; DOI=10.1038/bjc.1995.3; PMCID=PMC2033447

Yaginuma Y., Yamashita T., Takuma N., Katayama H., Ishikawa M.

Analysis of the p53 gene in human choriocarcinoma cell lines.

Br. J. Cancer 71:9-12(1995)

 

DOI=10.1007/0-306-46861-1_8

Ganapathy V., Prasad P.D., Leibach F.H.

Choriocarcinoma.

(In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.141-147; Kluwer Academic Publishers; New York; USA (1999)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=24098444; DOI=10.1371/journal.pone.0076205; PMCID=PMC3788803

Vuoristo S., Toivonen S., Weltner J., Mikkola M., Ustinov J., Trokovic R., Palgi J., Lund R.J., Tuuri T., Otonkoski T.

A novel feeder-free culture system for human pluripotent stem cell culture and induced pluripotent stem cell derivation.

PLoS ONE 8:E76205-E76205(2013)